Your Health, We Care
Stiripentol is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients taking clobazam who are 6 months of age and older and weighing 7 kg or more. There are no clinical data to support the use of Stiripentol as monotherapy in Dravet syndrome.
from FDA，2022.07
Stiripentol significantly reduces generalized seizures by enhancing GABAergic nerve conduction. Since its approval by the FDA, it has become an important drug to help patients cont···【more】
Article source：Lucius LaosRelease date：2024-08-29Recommended：149
Stiripentol is a drug that reduces seizures by modulating GABA receptors, especially for patients with Dravet syndrome. It has demonstrated significant efficacy in clinical trials,···【more】
Article source：Lucius LaosRelease date：2024-08-28Recommended：168
Stiripentol was approved by the FDA in 2018 for significantly improving seizure frequency and improving the quality of life of infants and young children suffering from Dravet synd···【more】
Article source：Lucius LaosRelease date：2024-08-28Recommended：182
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
